Therapeutic approaches for hepatobiliary disorders with ursodeoxycholic acid and bile-acid derivatives.
作者信息
Serfaty L, Poupon R
机构信息
Service d'Hépatologie, Hôpital Saint-Antoine, 184 Rue du Faubourg Saint-Antoine, 75571 Paris Cedex 12, France.
出版信息
Clin Res Hepatol Gastroenterol. 2012 Sep;36 Suppl 1:S1. doi: 10.1016/S2210-7401(12)70014-1.
Abstract
摘要
相似文献
1
Therapeutic approaches for hepatobiliary disorders with ursodeoxycholic acid and bile-acid derivatives.
Clin Res Hepatol Gastroenterol. 2012 Sep;36 Suppl 1:S1. doi: 10.1016/S2210-7401(12)70014-1.
2
Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action.
Clin Res Hepatol Gastroenterol. 2012 Sep;36 Suppl 1:S3-12. doi: 10.1016/S2210-7401(12)70015-3.
3
[Medical treatment of chronic cholestasis: ursodeoxycholic acid].
Gastroenterol Hepatol. 2000 Feb;23 Suppl 1:24-38.
4
[Hepatobiliary lesions in Crohn's disease and conservative methods of treatment].
Eksp Klin Gastroenterol. 2013(6):3-6.
5
[Treatment of cholestatic liver diseases with ursodeoxycholic acid].
Tidsskr Nor Laegeforen. 1997 Sep 30;117(23):3370-3.
6
[The characteristics of the use of ursodeoxycholic acid in chronic diseases of the hepatobiliary system].
Lik Sprava. 1995 Sep-Dec(9-12):47-8.
7
[Autoimmune cholestasis syndrome. Ursodeoxycholic acid is the drug standard].
MMW Fortschr Med. 2007 May 24;149(21):49.
8
9
[New aspects of pharmacological effects of ursodeoxycholic acid].
Eksp Klin Gastroenterol. 2014(8):4-10.
10
Ursodeoxycholic acid therapy in hepatobiliary disease.
Am J Med. 2000 Apr 15;108(6):481-6. doi: 10.1016/s0002-9343(00)00318-1.
引用本文的文献
1
Comparative potency of obeticholic acid and natural bile acids on FXR in hepatic and intestinal in vitro cell models.
Pharmacol Res Perspect. 2017 Dec;5(6). doi: 10.1002/prp2.368.
Zotero 插件